Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;38(6):2795-2820.
doi: 10.1007/s12325-021-01732-8. Epub 2021 Apr 30.

Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression

Eric P McMullen  1   2 , Yena Lee  1   2 , Orly Lipsitz  1   2 , Leanna M W Lui  1   2 , Maj Vinberg  3 , Roger Ho  4   5 , Nelson B Rodrigues  1   2 , Joshua D Rosenblat  1   2 , Bing Cao  6 , Hartej Gill  1   2 , Kayla M Teopiz  1 , Danielle S Cha  1   2 , Roger S McIntyre  7   8   9
Affiliations

Strategies to Prolong Ketamine's Efficacy in Adults with Treatment-Resistant Depression

Eric P McMullen et al. Adv Ther. 2021 Jun.

Abstract

Introduction: Ketamine treatment is capable of significant and rapid symptom improvement in adults with treatment-resistant depression (TRD). A limitation of ketamine treatment in TRD is the relatively short duration of time to relapse (e.g., median 2-4 weeks). The objective of the systematic review herein is to identify strategies capable of prolonging the acute efficacy of ketamine in adults with TRD.

Methods: PubMed/MEDLINE databases were searched from inception to December 2020 for clinical studies written in English using the following key terms: ketamine, prolong, and depression. A total of 454 articles were identified from the literature search which included all clinical studies regarding prolonging the antidepressant effects of ketamine. Twenty-two articles were included: ten randomized controlled trials (RCTs), eight prospective open-label trials, one retrospective chart review, and three case reports. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data extraction. The primary outcome was prolonged effect, defined as statistically significant antidepressant effects following acute ketamine treatment.

Results: A total of 454 articles were identified, and 22 articles were included. Different treatment modalites including pharmacological interventions, manualized-based psychotherapies, electroconvulsive therapy, transcranial magnetic stimulation, and intravenous monotherapy were examined to determine their impact on the prolongation of antidepressant effects following acute ketamine treatment. No treatment modality, other than repeat-dose IV ketamine, has demonstrated ability to significantly prolong the acute efficacy of IV ketamine in TRD.

Conclusion: Hitherto, available open-label data and controlled trial data support repeat administration of IV ketamine as an effective strategy to prolong the efficacy of ketamine's antidepressant effects (although not the focus of the study herein, maintenance repeat-dose esketamine treatment is proven effective in esketamine responders). There is a need to identify multimodality strategies that are safe and capable of prolonging the efficacy of ketamine in adults with TRD.

Keywords: Anxiety; Bipolar disorder; Depression; Esketamine; Ketamine; Major depressive disorder; Suicidality; Treatment-resistant depression.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart outlining the systematic literature research using PubMed/MEDLINE
See this image and copyright information in PMC

References

    1. Nestler E, Gould E, Manji H. Preclinical models: status of basic research in depression. Biol Psychiat. 2002;52(6):503–528. doi: 10.1016/S0006-3223(02)01405-1. - DOI - PubMed
    1. Best S, Pavel D, Haustrup N. Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: a long-term retrospective review of clinical use. Heliyon. 2019;5(8):e02187. doi: 10.1016/j.heliyon.2019.e02187. - DOI - PMC - PubMed
    1. McIntyre R, Filteau M, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7. doi: 10.1016/j.jad.2013.10.043. - DOI - PubMed
    1. Gaynes B, Warden D, Trivedi M, Wisniewski S, Fava M, Rush A. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv. 2009;60(11):1439–1445. doi: 10.1176/ps.2009.60.11.1439. - DOI - PubMed
    1. Stassen H, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993;3(2):127–135. doi: 10.1016/0924-977X(93)90264-M. - DOI - PubMed

Publication types

LinkOut - more resources